Press Releases
Evergreen Therapeutics Honored with Drug Development Innovation Award by BioTech Breakthrough
BioTech Breakthrough, a leading independent market intelligence organization evaluating top-tier innovations in the global life sciences and biotechnology sector, has announced the winners of its fifth annual BioTech Breakthrough Awards—with Evergreen Therapeutics receiving the Drug Development Innovation Award for the transformative role of its proprietary AI platform in accelerating pipeline development.
Evergreen Therapeutics Received FDA Clearance for EG-101 Phase I Clinical Trial
Evergreen Therapeutics announced that its AI‑enabled small molecule drug candidate EG‑101, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial.
Evergreen Therapeutics Announces Full Enrollment in Phase II Trial of EG-501
Evergreen Therapeutics has announced that patient enrollment has been completed for the Phase II clinical trial of EG‑501, its AI‑enabled drug candidate for cognitive impairment associated with neuropsychiatric systemic lupus erythematosus (NPSLE). The trial is being conducted in the United States.
Evergreen Therapeutics Announces Positive Results for EG-501 in Phase II Interim Analysis
Evergreen Therapeutics recently announced that its AI‑enabled candidate EG‑501 has reached a major milestone. The ongoing Phase II trial has completed enrollment of half its target participants, and an interim analysis of the data has returned positive outcomes.
Evergreen builds strategic partnership with leading CDMO BOJIMED
On June 5, 2023, BOJIMED and Evergreen signed a strategic cooperation agreement. Focusing on clinical trials, they will leverage AI to address R&D bottlenecks, boosting innovative drug development efficiency and commercialization.
Phase II Clearance of EG-301 Underscores Strategic Role of AI in Drug Development
The advancement of EG-301 underscores a reverse-translational approach empowered by Evergreen’s AI-driven clinical models, which enable precise indication prioritization and mechanistic insight.
